ZURICH (Reuters) - Swiss drugmaker Roche Holding AG said on Wednesday U.S. health regulators have granted priority review to its experimental leukemia treatment GA101. The U.S. Food and Drug Administration (FDA) grants priority reviews to medicines that are considered potentially significant therapeutic advancements over existing therapies. The FDA set a review date of December 20 for the drug as a treatment for previously untreated chronic lymphocytic leukemia, Roche said. ...
via Health News Headlines - Yahoo! News Read More Here..
No comments:
Post a Comment